



Hypoglycaemia Following Treatment of Hyperkalaemia with Intravenous Insulin

Samuel Ford^{1,2}, Shermin Fong³, Elizabeth Doran^{2,3}

1. RBWH Pharmacy Department 2. RBWH Emergency and Trauma Centre 3. The University of Queensland, School of Pharmacy

Purpose:

Intravenous insulin is commonly used for the treatment of hyperkalaemia in the Emergency and Trauma Centre but carries a risk of causing hypoglycaemia. Despite this being a well understood phenomenon, hypoglycaemia is common with international data suggesting that it occurs in up to a fifth of patients treated for hyperkalaemia¹. A retrospective audit was conducted to review the local rate of hypoglycaemia in the Emergency and Trauma Centre.

Methods:

Retrospective audit of adult patients admitted to the ETC from Jan 19' – June 20' who were found to be hyperkalaemic ($\geq 6.0 \text{ mmol/L}$)

Data collection

- Insulin/ glucose prescribed
- Blood glucose levels
- Presence of ESRF, T1DM, T2DM




Exclusion Criteria

- Haemolysed samples
- Patients who did not receive insulin
- Patients with DKA

Reviewed for hypoglycaemia ($\leq 3.9 \text{ mmol/L}$)
5 hours post insulin

Charts reviewed for hypoglycaemia morbidity

Results:



Conclusion:

Prescribing for hyperkalaemia was largely concordant (~96%) with the state-wide guideline. Despite this, hypoglycaemia was observed in 24% of patients with half requiring intervention. The severity of hypoglycaemia can be, in part, explained by inadequate blood glucose monitoring with 81% of patients receiving less than hourly blood glucose levels. It is crucial that clinicians monitor blood glucose levels hourly for at least 5 hours post intravenous insulin when given for hyperkalaemia.

1. Harel Z, Kamel K. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review. PLOS ONE. 2016;11(5):1-12.